BD (NYSE:BDX) shares ticked up before hours today on fourth-quarter results that came in ahead of the consensus forecast.
Shares of BDX rose more than 1% to $240.06 apiece at the opening of trading today.
The Franklin Lakes, New Jersey–based medtech giant reported profits of $421 million. That equals $1.45 per share on sales of $5.44 billion for the three months ended Sept. 30, 2024.
BD nearly quadrupled its bottom line year-over-year on a sales increase of 6.9%.
Adjusted to exclude one-time items, earnings per share came in at $3.81. That landed 4¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $5.38 billion in revenue.
BD’s Medical segment registered 11.1% year-over-year growth, bolstered by growth across medication delivery technology, including vascular access management, and double-digit growth in infusion, driven by the Alaris platform.
Interventional sales increased by 4.7%, driven by growth in both surgical and peripheral intervention products.
The fourth quarter also included BD’s $4.2 billion acquisition of the Edwards Lifesciences Critical Care business.
“In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences’ Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals,” said Tom Polen, chair, CEO and president of BD. “Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care. Combined with accelerated operational performance through BD Excellence and strong capital deployment, we are poised to deliver continued value creation for our shareholders.”
BD offered full-year guidance for 2025, projecting revenues between $21.9 billion and $22.1 billion. The company expects adjusted EPS to range between $14.25 and $14.60.
